Zhengye Biotechnology Holding Limited
NASDAQ: ZYBT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Songlin Song
- Employees
- 278
- Headquarters
- Jilin, China
- IPO year
- 2025
- Market cap
- $36.6M
- Website
- https://www.jlzybio.com
Loading ZYBT…
Loading profile data…Frequently asked questions about ZYBT
What does Zhengye Biotechnology Holding Limited (ZYBT) do?
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range e...
Where does ZYBT trade?
Zhengye Biotechnology Holding Limited (ZYBT) trades on the NASDAQ Capital Market.
What sector is ZYBT in?
Zhengye Biotechnology Holding Limited (ZYBT) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Zhengye Biotechnology Holding Limited?
Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Limited (ZYBT).
Where is Zhengye Biotechnology Holding Limited headquartered?
Zhengye Biotechnology Holding Limited is headquartered in China.
Does ZYBT pay a dividend?
Zhengye Biotechnology Holding Limited (ZYBT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZYBT go public?
Zhengye Biotechnology Holding Limited (ZYBT) completed its initial public offering in 2025.